Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 4
2007 6
2008 6
2009 3
2010 3
2011 6
2012 7
2013 1
2014 3
2017 1
2018 2
2019 6
2020 9
2021 6
2022 5
2023 19
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma.
Teishima J, Hara T, Tobe T, Hirata J, Ueki H, Wakita N, Shiraishi Y, Okamura Y, Bando Y, Terakawa T, Furukawa J, Harada KI, Nakano Y, Fujisawa M. Teishima J, et al. Among authors: nakano y. Can Urol Assoc J. 2024 Jan 30. doi: 10.5489/cuaj.8548. Online ahead of print. Can Urol Assoc J. 2024. PMID: 38319607 Free article.
The harmful effects of overlooking acute bacterial prostatitis.
Yang Y, Shigemura K, Maeda K, Moriwaki M, Chen KC, Nakano Y, Fujisawa M. Yang Y, et al. Among authors: nakano y. Int J Urol. 2024 May;31(5):459-463. doi: 10.1111/iju.15390. Epub 2024 Jan 18. Int J Urol. 2024. PMID: 38239011 Review.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free article. Clinical Trial.
Cine magnetic resonance imaging predicts thrombus adhesion in metastatic renal cell carcinoma with an inferior vena cava tumor thrombus: A case of pathological complete response with pembrolizumab plus lenvatinib.
Hara T, Furukawa J, Tsutiya T, Kodama T, Uehara K, Terakawa T, Harada K, Teishima J, Nakano Y, Fujisawa M. Hara T, et al. Among authors: nakano y. IJU Case Rep. 2023 Nov 8;7(1):60-63. doi: 10.1002/iju5.12668. eCollection 2024 Jan. IJU Case Rep. 2023. PMID: 38173458 Free PMC article.
Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Kato T, Nakano Y, Hongo F, Katano H, Miyagawa T, Ueda K, Azuma H, Nozawa M, Hinata N, Hori J, Otoshi T, Shimizu N, Aizawa M, Osada S, Matsui A, Oya M, Eto M, Tomita Y, Shinohara N, Uemura H. Kato T, et al. Among authors: nakano y. Int J Urol. 2024 Mar;31(3):265-272. doi: 10.1111/iju.15345. Epub 2023 Dec 18. Int J Urol. 2024. PMID: 38110838
82 results